Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Showing VOYXACT® (sibeprenlimab-szsi) Preserved Kidney Function Over 12 Months in IgA Nephropathy (IgAN)

Submitted by Anonymous on

PRINCETON, N.J. & TOKYO, June 04, 2026--Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that VOYXACT® (sibeprenlimab-szsi) preserved kidney function compared to placebo over 12 months in adults with primary IgA nephropathy (IgAN) at...

Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Showing VOYXACT® (sibeprenlimab-szsi) Preser

Submitted by Anonymous on

This release is intended for U.S. audiences only - Strong findings support VOYXACT, the first and only U.S. FDA-approved selective APRIL inhibitor, as an early, targeted therapy that addresses key drivers of disease progression: preserving kidney function and reducing Gd-IgA1,...

Case Report: Dynamic TKI combination strategies for EGFR-mutant NSCLC with acquired ROS1 fusion and brain metastases

Submitted by Anonymous on

The development of a ROS1 fusion as a bypass signaling pathway mediating resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) is rare, with Case presentationDiagnostic assessment In August 2019, a 61-year-old woman with no smoking history or family history of...

Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Showing VOYXACT® (sibeprenlimab-szsi) Preserved Kidney Function Over 12 Months in IgA Nephropathy (IgAN)

Submitted by Anonymous on

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that VOYXACT® (sibeprenlimab-szsi) preserved kidney function compared to placebo over 12 months in adults with primary IgA nephropathy (IgAN) at risk for...

ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs

Submitted by Anonymous on

ALX Oncology NASDAQ: ALXO executives said the company is focused on advancing two clinical-stage oncology programs, with upcoming data readouts expected to shape potential later-stage development plans for its lead CD47 program, evorpacept, and its EGFR-targeted antibody-drug conjugate, ALX2004. Speaking...

Beyond Sidedness: DNA Methylation as a Biomarker to Refine Anti-EGFR Treatment Selection in RAS/BRAF Wild-type Metastatic Colorectal Cancer

Submitted by Anonymous on

Abstract Primary tumor sidedness is a major determinant of biologic-agent selection in RAS/BRAF wild-type metastatic colorectal cancer (mCRC), but it remains an anatomic surrogate rather than a mechanistic biomarker. Genome-wide DNA methylation status has emerged as a biologically informative classifier...

Who Truly Benefits from Anti-EGFR Rechallenge in Metastatic Colorectal Cancer? From Clinical Enrichment to ctDNA-Guided Molecular Hyperselection

Submitted by Anonymous on

Abstract Later-line treatment of metastatic colorectal cancer (mCRC) remains challenging because established salvage options often provide limited objective response and predominantly cytostatic benefit. Anti-epidermal growth factor receptor (EGFR) rechallenge has re-emerged as a rational strategy for a selected subgroup of...

Integrated isothermal shift assay and multi-omics identify melittin as a novel EGFR-targeting peptide to suppress NSCLC

Submitted by Anonymous on

AbstractBackground Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, highlighting the urgent need for novel therapeutic agents. Melittin (MEL), a bioactive peptide, exhibits potent antitumor activity; however, its clinical translation is limited by an incomplete understanding...

Subscribe to Newsfeed